|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO008456747 |
| 003 |
DE-627 |
| 005 |
20230425181714.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
220512s2023 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)WHO008456747
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2021-006951-32-DE
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)REP0321
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2021-006951-32-AT
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia.
|b Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase IIItrial. (REPAVID-22)
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 16-02-2022, Last updated: 2023-02-02
|
| 650 |
|
4 |
|a Medical Condition: COVID-19 and other community-acquired pneumonia MedDRA version: 20.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 30. Jan.
|
| 773 |
1 |
8 |
|g year:2023
|g day:30
|g month:01
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-006951-32
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 30
|c 01
|
Klinische Studie